Blair Shamel Email

Member Board Directors, Strategic Consultant . Nanospectra Biosciences

Current Roles

Employees:
2
Revenue:
$3.5M
About
Nanospectra Biosciences is a medical device company pioneering a patient-centric use of nanomedicine for selective thermal ablation. AuroLase, the company's lead product for the ablation of prostate cancer tissue, is the first and only ultra-focal tissue ablation therapy designed to maximize treatment efficacy while minimizing side effects typically associated with surgery, radiation, and traditional focal therapies. Implementing a multi-prong growth strategy, Nanospectra is focusing on clinical advancements, exclusive partnering agreements and ongoing research and development. Nanospectra’s technology development has been funded to date by a series of grants, private equity investments and corporate partnerships.
Nanospectra Biosciences Address
8285 El Rio Street
Houston, TX
Nanospectra Biosciences Email

Past Companies

Nanospectra Biosciences, Inc.Member of Board of Directors, Strategic Consultant
Sognef, Inc.Chief Operating Officer
The Shamel Group IncorporatedPresident

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.